Ceftaroline Fosamil

Summary

Ceftaroline Fosamil (CHEMBL501122) is an approved small-molecule antibacterial drug (ATC J01DI02); indicated across 8 conditions including bacterial infectious disease and bacterial pneumonia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DI02
• Indications: 8 conditions
• Clinical trials: 39
• Chemistry: 684.7 Da · C22H21N8O8PS4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL501122
Name	Ceftaroline Fosamil
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9852981
ChEBI	CHEBI:70718
ATC	J01DI02
Molecular formula	C22H21N8O8PS4
Molecular weight	684.7
InChIKey	ZCCUWMICIWSJIX-NQJJCJBVSA-N

SMILES: CCO/N=C(/C1=NSC(=N1)NP(=O)(O)O)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-]

IUPAC name: (6R,7R)-7-[[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

ChEBI definition: A cephalosporin having [4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl]sulfanyl and {(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl}amino side groups located at positions 3 and 7 respectively. The N-phospho prodrug of ceftaroline, a broad-spectrum antibiotic active against methicillin-resistant Staphylococcus aureus (MRSA). It is used for the treatment of adults with acute bacterial skin and skin structure infections.

Pharmacological roles (ChEBI): antibacterial drug, antimicrobial agent, prodrug.

Also known as: Ceftarolina fosamilo, Ceftaroline fosamil, Ceftaroline fosamil anhydrous, PPI-0903, TAK 599, TAK-599, TAK599, Teflaro, ceftaroline, Ceftaroline, CEFTAROLINE FOSAMIL, ceftaroline fosamil

Parent form; salt/anhydrous children: CHEMBL3544973, CHEMBL4790265

Patent coverage: 465 distinct patent families (1,007 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
bacterial pneumonia	3	MONDO:0004652	EFO:1001272
urinary tract infection	2	MONDO:0100338	EFO:0003103
kidney disorder	1	MONDO:0005240	EFO:0003086

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 39.

Phase distribution

Phase	Trials
PHASE4	15
PHASE1	10
PHASE3	8
PHASE2	3
PHASE2/PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01298843	PHASE4	COMPLETED	Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
NCT01524302	PHASE4	COMPLETED	Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia
NCT01645735	PHASE4	COMPLETED	Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
NCT01666743	PHASE4	WITHDRAWN	Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia
NCT01669980	PHASE4	COMPLETED	Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)
NCT01701219	PHASE4	COMPLETED	Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
NCT01734694	PHASE4	TERMINATED	Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
NCT02005068	PHASE4	WITHDRAWN	Ceftaroline in the Treatment of Bone and Joint Infections
NCT02307006	PHASE4	UNKNOWN	The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection
NCT02582203	PHASE4	COMPLETED	Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA
NCT02660346	PHASE4	COMPLETED	IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
NCT02937181	PHASE4	UNKNOWN	Antibiotic Prophylaxis in Open Fractures
NCT03771313	PHASE4	COMPLETED	Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis
NCT05156437	PHASE4	TERMINATED	Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
NCT05977868	PHASE4	TERMINATED	Comparing Oral Versus Parenteral Antimicrobial Therapy
NCT02735707	PHASE3	RECRUITING	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT00423657	PHASE3	COMPLETED	Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
NCT00424190	PHASE3	COMPLETED	Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
NCT00509106	PHASE3	COMPLETED	Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
NCT00621504	PHASE3	COMPLETED	Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
NCT01371838	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
NCT01400867	PHASE2/PHASE3	COMPLETED	Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections
NCT01499277	PHASE3	COMPLETED	Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
NCT01530763	PHASE2/PHASE3	COMPLETED	Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
NCT02202135	PHASE3	TERMINATED	Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
NCT00633152	PHASE2	COMPLETED	Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections
NCT01281462	PHASE2	COMPLETED	Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections
NCT02335905	PHASE1/PHASE2	COMPLETED	Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
NCT02424734	PHASE2	TERMINATED	Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis
NCT00633126	PHASE1	COMPLETED	Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age
NCT01290900	PHASE1	COMPLETED	A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
NCT01458743	PHASE1	COMPLETED	Ceftaroline China Pharmacokinetics Study
NCT01612507	PHASE1	COMPLETED	A Study to Assess Safety, Tolerability and Pharmacokinetics of Ceftaroline in Healthy Subjects
NCT01624246	PHASE1	COMPLETED	Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance
NCT01648127	PHASE1	COMPLETED	Pharmacokinetics of Ceftaroline in Normal and Obese Subjects
NCT01664065	PHASE1	COMPLETED	A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects
NCT02600793	PHASE1	UNKNOWN	Ceftaroline Diffusion Into Cerebrospinal Fluid of Children
NCT02806882	PHASE1	COMPLETED	Penetration of Ceftaroline Into Cerebrospinal Fluid(CSF)
NCT03025841	PHASE1	COMPLETED	Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Normal or Augmented Renal Clearance

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).